Under the leadership of Dr. Alex Zhavoronkov, founder, co-CEO, and Chief Business Officer, Insilico Medicine will engage with global biopharma stakeholders, investors, and researchers at Booth #4021 during the convention. The company is set to demonstrate the prowess of its comprehensive Pharma.AI platform, revealing its integrated approach that harnesses AI, quantum computing, and laboratory automation to accelerate drug candidate identification and optimization.

Insilico’s presence at BIO 2026 will include three high-profile speaking slots covering diverse topics that reflect the intersection of biotechnology and emerging technology. These sessions are titled “ADCs, GLP-1s, and Beyond: How China is Impacting the 2026 BD Landscape,” “Quantum Computing in Drug Discovery,” and “Strategic Innovation: Building Smarter Pipelines for Challenging Targets.” Each talk will elucidate how the fusion of cutting-edge computational techniques with traditional drug discovery reshapes therapeutic innovation landscapes.

At the forefront of this innovation is Insilico’s adept use of generative AI models to streamline target identification and compound optimization. Their strategy leverages quantum algorithms to process complex biological datasets with unprecedented speed, thereby expediting the discovery cycle. Automation labs, such as the proprietary LifeStar 2, enable rapid synthesis and biological evaluation of candidate molecules, creating a seamless end-to-end platform that vastly reduces time and cost compared to conventional methods.

Crucially, Insilico Medicine’s approach emphasizes de-risking drug development through meticulous early-stage program design. By integrating advanced validation strategies with milestone-driven execution protocols, the company not only accelerates candidate progression but also increases the probability of clinical success, an advancement poised to transform the pharmaceutical industry.

“BIO 2026 International Convention serves as a critical nexus for collaboration driving biotech innovation,” Dr. Zhavoronkov stated. “We are eager to demonstrate how our Pharma.AI platform, alongside cutting-edge laboratory technologies and the MMAI Gym for Science, is rapidly expediting the discovery of novel therapeutics. Our mission is to create partnerships to extend healthier lifespans globally through innovative medical solutions.”

Insilico Medicine’s competitive edge is reflected in an extraordinary pace of development. Traditional early-stage drug discovery typically spans 2.5 to 4 years, with the need to synthesize and screen thousands of compounds. By contrast, Insilico’s AI-powered platform has nominated 30 preclinical candidates within an average timeframe of 12 to 18 months per program, testing only 60 to 200 molecules per project — a testament to the precision and efficiency afforded by AI-driven workflows.

Among its pipeline highlights is Rentosertib, the world’s first anti-fibrotic drug candidate discovered through AI with a novel mechanism of action. This molecule has completed a Phase 2a proof-of-concept trial, demonstrating promising efficacy and safety signals. Additionally, ISM5411, a PHD1/2 inhibitor intended for inflammatory bowel disease, has successfully passed two Phase 1 trials, showing an optimal safety profile and gut-restricted pharmacokinetics, further validating Insilico’s translational capabilities.

Moreover, three of Insilico’s anti-tumor programs have now progressed into first-in-patient dosing stages, with interim data eagerly anticipated by the scientific and medical communities. This rapid clinical advancement underscores the company’s ability to convert AI-derived insights into tangible therapeutic candidates within highly competitive timelines.

Since its inception in 2014, Insilico Medicine has amassed more than 200 peer-reviewed publications, rigorously documenting its scientific breakthroughs at the confluence of biotechnology, artificial intelligence, and automated drug discovery. Its commitment to open science and innovation has earned it a place among the Top 100 global corporate institutions according to Nature Index’s 2025 Research Leaders ranking, highlighting its influence on biological and natural sciences research.

The company continues to diversify beyond pharmaceuticals by deploying its Pharma.AI platform across industries such as advanced materials, agriculture, nutritional products, and veterinary medicine, paving the way for AI-driven innovation that extends well beyond traditional drug development.

Listing on the Hong Kong Stock Exchange in late 2025 further positions Insilico Medicine as a front-runner on the global biotech investment landscape. With deepening collaborations and technological advancements, the company is primed to shape the future of precision medicine and longevity science.

For more detailed insights into Insilico Medicine’s transformative technologies and strategic initiatives, attendees and interested parties are encouraged to visit the company’s booth and attend its BIO 2026 presentations. The integration of generative AI, quantum computing, and automation heralds a new era where drug discovery is not only faster and more cost-effective but also significantly more predictive and innovative.

Subject of Research: Artificial Intelligence in Drug Discovery and Quantum Computing Applications in Biotechnology

Article Title: Pioneering the Future of Drug Discovery: Insilico Medicine’s Groundbreaking Innovations at BIO 2026

News Publication Date: May 29, 2025

Web References: https://bio2026.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=00645188, www.insilico.com

Image Credits: BIO 2026

Keywords: AI-driven drug discovery, generative AI, quantum computing, pharmaceutical innovation, clinical-stage biotechnology, automation in drug discovery, Rentosertib, ISM5411, Pharma.AI platform, Longevity science, biotech investment, preclinical drug candidates

At the core of this alliance lies Insilico Medicine’s validated and sophisticated AI platform, which leverages generative artificial intelligence and automated processes to accelerate and refine the early stages of drug R&D. Traditionally, the path from initial compound identification to preclinical candidate nomination can span several years and involve extensive resource expenditure. Insilico’s Pharma.AI platform disrupts this timeline by employing advanced algorithms for target discovery, molecular design, and optimization, enabling the synthesis and testing of only a fraction of molecules necessary in conventional workflows, thereby delivering preclinical candidates in a significantly reduced timeframe of 12 to 18 months.

CMS brings to this collaboration decades of industry expertise in drug lifecycle management and a robust infrastructure for clinical development and regulatory navigation. Their adeptness in designing clinical strategies, managing trial executions, and orchestrating market commercialization creates an ideal complement to Insilico’s cutting-edge computational capabilities. Together, the two entities are positioned to revolutionize the drug development pipeline by fostering a seamless integration from computational design to clinical reality.

The partnership aims to advance no fewer than two joint R&D programs, with CMS providing substantial funding support and operational resources. This strategic engagement is designed to optimize decision-making through collaborative governance structures, improving development efficiency and enhancing the probability of clinical success. The initiative’s ambition extends beyond mere speed, seeking to holistically elevate the quality of candidate molecules and streamline their translation from laboratory benches to patients’ bedsides.

This co-development model epitomizes the future of pharmaceutical innovation in which artificial intelligence and human expertise coalesce to overcome the longstanding challenges of drug discovery. Insilico’s AI-enabled methodology facilitates precise screening and validation of potential therapeutic compounds, drastically reducing the attrition rates that have traditionally plagued new drug candidates. CMS’ extensive clinical networks and regulatory expertise will ensure that promising discoveries experience expedited and efficient progression through clinical trials, regulatory approval, and eventual market introduction.

Insilico Medicine’s leadership in AI-driven drug discovery is founded on a track record of nominating 20 preclinical candidates across multiple therapeutic areas in just a three-year span, demonstrating unparalleled efficiency relative to conventional timelines. This acceleration is particularly imperative in central nervous system and autoimmune diseases, where unmet medical needs persist, and traditional therapeutic development has encountered significant barriers due to the complexity of these conditions.

The integration of AI with automation not only shortens the discovery timeline but also allows for a more diversified exploration of chemical space, improving the likelihood of identifying novel mechanisms of action and optimizing pharmacokinetic and safety profiles. This enhanced throughput and precision underpin the collaborative efforts, providing a scientific foundation geared toward developing differentiated and impactful therapeutic options.

CMS’s commitment to enriching their pipeline with first-in-class and best-in-class innovative assets aligns seamlessly with Insilico’s technology-driven approach, creating a powerful synergy. By merging deep disease-area expertise with AI capabilities, the partnership is poised to unlock new frontiers in clinical research, transforming promising molecular entities into clinically viable therapeutics.

Looking forward, both organizations have expressed a commitment to expanding the scope of their collaboration beyond initial projects. This includes multi-dimensional cooperation across pipeline development phases, clinical strategy refinement, and the cultivation of global partnerships. Such comprehensive integration is intended to broaden the accessibility and affordability of advanced medicines, ultimately enhancing patient outcomes and quality of life on a global scale.

The scientific community and industry observers view this collaboration as a pioneering model that blends high-technology innovation with practical, on-the-ground pharmaceutical development. It exemplifies the emerging paradigm shift in R&D where computational power and human clinical insight intersect to deliver impactful medical solutions more rapidly and efficiently than ever before.

Insilico Medicine has demonstrated that AI can dramatically condense traditionally lengthy preclinical timelines, synthesizing and validating hundreds rather than thousands of candidate molecules to identify viable leads. This efficiency spike is critical in accelerating the translation of ‘proof of concept’ molecules into successful clinical candidates, a process historically burdened by high failure rates and excessive cost.

As this partnership unfolds, it may set new standards and expectations for collaborative drug research initiatives worldwide. By seamlessly merging AI-empowered innovation with proven clinical and commercialization capabilities, Insilico and CMS highlight the future trajectory of life sciences — one that is data-driven, patient-centric, and globally impactful.

Subject of Research:
Advancing AI-powered drug discovery and development focusing on central nervous system and autoimmune diseases.

Article Title:
Insilico Medicine and China Medical System Announce Strategic AI-Enabled Collaboration to Accelerate Drug Discovery in CNS and Autoimmune Disorders

News Publication Date:
February 10, 2026

Web References:
www.insilico.com

Image Credits:
Insilico Medicine

Keywords:
Generative AI, Central nervous system, Immune disorders, Small molecules

Insilico Medicine’s AI platform, Pharma.AI, harnesses deep generative models integrated with reinforcement learning and transformer architectures to identify novel drug targets and simultaneously generate optimized small molecules. This simultaneous process accelerates drug discovery markedly beyond traditional laborious methods. Rentosertib embodies this innovation: it emerged from a pipeline wherein computational biology and chemistry were unified, resulting in a first-in-class therapeutic candidate targeting Traf2- and NCK-interacting kinase (TNIK), a protein kinase implicated in fibrotic processes within lung tissue.

Idiopathic pulmonary fibrosis is a relentless, fatal disease characterized by progressive lung scarring and functional decline. Despite antifibrotic drugs approved in the last decade, the median survival remains limited to three to four years, underscoring the urgent need for novel treatments with greater efficacy and disease-modifying potential. By specifically inhibiting TNIK, Rentosertib aims to disrupt cellular signaling pathways driving excessive extracellular matrix deposition, thereby halting or even reversing fibrosis progression.

The GENESIS-IPF trial enrolled 71 patients diagnosed with IPF across 22 sites in China. Participants were randomized to receive placebo or varying doses of Rentosertib: 30 mg once daily (QD), 30 mg twice daily (BID), or 60 mg QD for 12 weeks. The study’s primary endpoint assessed safety and tolerability, and Rentosertib met these criteria with a manageable profile of adverse events. Treatment-emergent adverse events (TEAEs) occurred at similar rates across all cohorts and were predominantly mild to moderate in severity, with serious adverse events being rare and resolving after discontinuation.

Perhaps most strikingly, the trial demonstrated a dose-dependent improvement in lung function, assessed by forced vital capacity (FVC)—the gold-standard clinical measure of pulmonary performance in IPF. The highest dose cohort (60 mg QD) experienced a mean FVC increase of +98.4 mL, contrasting with a mean decline of -20.3 mL observed in the placebo group over 12 weeks. Such data suggest Rentosertib’s potential not only to halt lung function decline but also to promote functional recovery, an unprecedented outcome in this challenging disease.

Beyond clinical endpoints, the study included an exploratory biomarker analysis of patient serum proteins to validate the mechanism of action and identify potential prognostic indicators. Results revealed significant, dose- and time-dependent modulation of profibrotic and inflammatory mediators. Notably, proteins heavily implicated in fibrosis such as COL1A1, MMP10, and fibroblast activation protein (FAP) were markedly reduced in the high-dose group, while anti-inflammatory cytokine IL-10 levels increased. These protein dynamics closely paralleled improvements in FVC readings, reinforcing the biological plausibility of TNIK inhibition reducing fibrosis.

This trial exemplifies the distinctive advantage of AI-driven approaches: rapid discovery, rational design, and swift translation to clinical proof-of-concept. Insilico Medicine’s generative AI platform compressed the traditional drug discovery timeline significantly, achieving candidate nomination within 12–18 months from project inception. This is in stark contrast to the typical 2.5 to 4 years historically required to identify and develop preclinical candidates, demonstrating AI’s power to dramatically accelerate pharmaceutical innovation.

The implications of this work extend beyond IPF. The TNIK kinase, once a relatively obscure target, was prioritized through AI-driven systems analyzing vast datasets to identify novel molecular targets linked to fibrotic pathways. Rentosertib showcases how algorithmically guided target discovery can illuminate previously untapped biological mechanisms and translate rapidly into therapeutics with potential cross-disease applications, including other fibrotic or inflammatory disorders.

Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, emphasized that these findings propel the pharmaceutical industry into a new era where AI is integral not just to early discovery but throughout clinical development. “Rentosertib’s Phase IIa results demonstrate both safety and encouraging efficacy, warranting larger and longer studies,” he stated. “This represents a paradigm shift, underscoring AI’s transformative potential to unlock therapies faster and at lower costs.”

Lead investigator Dr. Zuojun Xu, from Peking Union Medical College, noted the clinical significance of these findings against the backdrop of IPF’s unmet needs. While cautioning that the relatively small sample sizes necessitate further validation, Dr. Xu conveyed optimism about Rentosertib’s disease-modifying potential given the clear dose-response in lung function and biomarker modulation. This pioneering AI-developed molecule could fill a critical void in IPF treatment strategies.

The success of Rentosertib also underscores a new paradigm in drug development efficiency. Insilico’s sophisticated AI platforms streamline the synthesis and biological testing of far fewer candidate molecules—roughly 60 to 200 per project—compared to thousands screened historically. The company reports a remarkable 100% progression rate from nominated preclinical candidates to Investigational New Drug (IND)-enabling development, underscoring the precision and predictive power of AI-generated drug design.

Moving forward, Insilico Medicine is in dialogue with regulatory agencies to initiate larger-scale, longer-duration clinical trials necessary to confirm Rentosertib’s therapeutic benefit and safety in diverse patient populations. The company’s integration of AI with automation and cutting-edge molecular biology heralds a new frontier in the rapid translation of digital discoveries into tangible clinical advances.

In conclusion, Rentosertib’s compelling Phase IIa results mark a seminal achievement in the history of AI-assisted drug development. This study not only provides hope for IPF patients facing a dire prognosis but also validates the promise of AI as a game-changing tool in the complex arena of drug discovery and development. The fusion of computational intelligence and clinical science embodied by Rentosertib paves the way for accelerated innovation and more personalized, effective therapies across a spectrum of debilitating diseases.

Subject of Research:
Idiopathic Pulmonary Fibrosis and AI-driven drug discovery targeting TNIK kinase.

Article Title:
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

News Publication Date:
3-Jun-2025

Web References:
http://dx.doi.org/10.1038/s41591-025-03743-2

References:
Nature Medicine, Volume 58, Issue 7, June 3, 2025

Image Credits:
Nature Medicine

Keywords:
Generative AI, Clinical trials, Fibrosis, Drug discovery, Molecular targets, Small molecule inhibitors